Title |
B Cell Modulation Strategies in Autoimmune Diseases: New Concepts
|
---|---|
Published in |
Frontiers in immunology, April 2018
|
DOI | 10.3389/fimmu.2018.00622 |
Pubmed ID | |
Authors |
Philippe Musette, Jean David Bouaziz |
Abstract |
B cells are major effector cells in autoimmunity through antibody production, T cell help and pro-inflammatory cytokine production. Major advances have been made in human B cell biology knowledge using rituximab and type II new anti-CD20 antibodies, anti-CD19 antibodies, anti-CD22 antibodies, autoantigen specific B cell depleting therapy (chimeric antigen receptor T cells), and B cell receptor signaling inhibition (Bruton's tyrosine kinase inhibitors). However, in certain circumstances B cell depleting therapy may lead to the worsening of the autoimmune disease which is in accordance with the existence of a regulatory B cell population. Current concepts and future directions for B cell modulating therapies in autoimmune diseases with a special focus on pemphigus are discussed. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Australia | 2 | 15% |
Spain | 1 | 8% |
Malaysia | 1 | 8% |
Mexico | 1 | 8% |
Canada | 1 | 8% |
United States | 1 | 8% |
Switzerland | 1 | 8% |
Unknown | 5 | 38% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 11 | 85% |
Scientists | 2 | 15% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 143 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 21 | 15% |
Student > Master | 19 | 13% |
Researcher | 15 | 10% |
Student > Doctoral Student | 15 | 10% |
Student > Bachelor | 12 | 8% |
Other | 27 | 19% |
Unknown | 34 | 24% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 28 | 20% |
Biochemistry, Genetics and Molecular Biology | 23 | 16% |
Immunology and Microbiology | 19 | 13% |
Agricultural and Biological Sciences | 14 | 10% |
Engineering | 4 | 3% |
Other | 14 | 10% |
Unknown | 41 | 29% |